WO2022258794A3 - A conjugate - Google Patents

A conjugate Download PDF

Info

Publication number
WO2022258794A3
WO2022258794A3 PCT/EP2022/065777 EP2022065777W WO2022258794A3 WO 2022258794 A3 WO2022258794 A3 WO 2022258794A3 EP 2022065777 W EP2022065777 W EP 2022065777W WO 2022258794 A3 WO2022258794 A3 WO 2022258794A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell epitope
sequence
conjugate
polypeptide
amino acids
Prior art date
Application number
PCT/EP2022/065777
Other languages
French (fr)
Other versions
WO2022258794A2 (en
Inventor
Dana Michel
Mikael GRANATH
Ulf Tedebark
Gustav Gaudernack
Roald Skurtveit
Sara Mangsbo
Original Assignee
Ultimovacs Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimovacs Ab filed Critical Ultimovacs Ab
Priority to MX2023014654A priority Critical patent/MX2023014654A/en
Priority to IL309180A priority patent/IL309180A/en
Priority to JP2023575731A priority patent/JP2024522178A/en
Priority to CA3222077A priority patent/CA3222077A1/en
Priority to EP22733376.2A priority patent/EP4351634A2/en
Priority to CN202280055181.0A priority patent/CN117940152A/en
Priority to KR1020247000725A priority patent/KR20240046703A/en
Priority to AU2022290634A priority patent/AU2022290634A1/en
Publication of WO2022258794A2 publication Critical patent/WO2022258794A2/en
Publication of WO2022258794A3 publication Critical patent/WO2022258794A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

A conjugate comprising at least one polypeptide comprising a sequence of a B-cell epitope and at least one polypeptide comprising a sequence of a CD4+ T-cell epitope is provided. The CD4+ T-cell epitope comprises a region of at least 12 amino acids of a universal tumour antigen or a sequence having at least 80% sequence identity to the region and the CD4+ T-cell epitope is immunogenic in at least 50% of the population. The at least one polypeptide comprising the sequence of the CD4+ T-cell epitope is equal to or less than 500 amino acids in length. The sequence of the B-cell epitope is different from the sequence of the CD4+ T-cell epitope and an antibody specific for the B-cell epitope binds to the conjugate.
PCT/EP2022/065777 2021-06-09 2022-06-09 A conjugate WO2022258794A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2023014654A MX2023014654A (en) 2021-06-09 2022-06-09 A conjugate.
IL309180A IL309180A (en) 2021-06-09 2022-06-09 A conjugate
JP2023575731A JP2024522178A (en) 2021-06-09 2022-06-09 Conjugates
CA3222077A CA3222077A1 (en) 2021-06-09 2022-06-09 A conjugate
EP22733376.2A EP4351634A2 (en) 2021-06-09 2022-06-09 A conjugate
CN202280055181.0A CN117940152A (en) 2021-06-09 2022-06-09 Conjugate(s)
KR1020247000725A KR20240046703A (en) 2021-06-09 2022-06-09 zygote
AU2022290634A AU2022290634A1 (en) 2021-06-09 2022-06-09 A conjugate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21178648 2021-06-09
EP21178648.8 2021-06-09

Publications (2)

Publication Number Publication Date
WO2022258794A2 WO2022258794A2 (en) 2022-12-15
WO2022258794A3 true WO2022258794A3 (en) 2023-01-19

Family

ID=76374946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/065777 WO2022258794A2 (en) 2021-06-09 2022-06-09 A conjugate

Country Status (9)

Country Link
EP (1) EP4351634A2 (en)
JP (1) JP2024522178A (en)
KR (1) KR20240046703A (en)
CN (1) CN117940152A (en)
AU (1) AU2022290634A1 (en)
CA (1) CA3222077A1 (en)
IL (1) IL309180A (en)
MX (1) MX2023014654A (en)
WO (1) WO2022258794A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130071428A1 (en) * 2010-03-15 2013-03-21 Stichting Voor De Technische Wetenschappen Peptides, conjugates and method for increasing immunogenicity of a vaccine
US20170202938A1 (en) * 2016-01-19 2017-07-20 Pfizer Inc. Cancer Vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2536830T (en) 2010-02-16 2019-11-11 Ultimovacs Asa Polypeptides
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130071428A1 (en) * 2010-03-15 2013-03-21 Stichting Voor De Technische Wetenschappen Peptides, conjugates and method for increasing immunogenicity of a vaccine
US20170202938A1 (en) * 2016-01-19 2017-07-20 Pfizer Inc. Cancer Vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIAO ZHONG-LI ET AL: "Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 16, no. 4, 25 May 2013 (2013-05-25), pages 444 - 450, XP028565830, ISSN: 1567-5769, DOI: 10.1016/J.INTIMP.2013.05.006 *
SARA M. MANGSBO ET AL: "Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses", MOLECULAR IMMUNOLOGY, vol. 93, 1 January 2018 (2018-01-01), GB, pages 115 - 124, XP055765720, ISSN: 0161-5890, DOI: 10.1016/j.molimm.2017.11.004 *

Also Published As

Publication number Publication date
JP2024522178A (en) 2024-06-11
AU2022290634A1 (en) 2024-01-25
KR20240046703A (en) 2024-04-09
EP4351634A2 (en) 2024-04-17
CA3222077A1 (en) 2022-12-15
WO2022258794A2 (en) 2022-12-15
MX2023014654A (en) 2024-04-12
IL309180A (en) 2024-02-01
CN117940152A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
EP0245078B1 (en) Enhancement of antigen immunogenicity
RU95105991A (en) Conjugate, vaccine, methods of immunogenicity enhancement, methods of immunization
AU677592B2 (en) Potentiation of immunogenic response
BR9912177A (en) Artificial helper cell epitopes as immunostimulators for synthetic peptide immunogens
CO4850562A1 (en) PROCESS TO PRODUCE A CONCENTRATED PREPARATION OF ANTIBODIES
WO2022258794A3 (en) A conjugate
EP1450857A4 (en) Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
CA2124126A1 (en) Monoclonal antibodies and fv specific for cd2 antigen
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
EP0279688A3 (en) Methods and compositions for the use of hiv env polypeptides and antibodies thereto
MX2022015734A (en) Modified exotoxin a proteins.
IS4922A (en) Polypeptides capable of forming antigen-specific forms of specificity for the resus D antigen, the DNA that represents them, and the method of preparing a saline and its use
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
PE20240819A1 (en) ANTI-HLA-G ANTIBODIES AND THEIR USE
ES2137310T3 (en) VACCINE AGAINST STREPTOCOCCUS SUIS INFECTION.
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
CA2360382A1 (en) Use of antibodies for the vaccination against cancer
US5095094A (en) A43 kDa antigenic protein of Bordetella recognized by polyclonal antibodies to adenylate cyclase but devoid of calmodulin-activatable adenylate cyclase activity
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
WO2021163562A3 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Yu et al. Peptide‐antibody conjugates for tumour therapy: A MHC‐class‐II‐restricted tetanus toxin peptide coupled to an anti‐IG light chain antibody can induce cytotoxic lysis of a human B‐cell lymphoma by specific CD4 T cells
ATE256745T1 (en) THERAPEUTIC AND PREVENTIVE VACCINE AGAINST HIV

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22733376

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: MX/A/2023/014654

Country of ref document: MX

Ref document number: 309180

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2023575731

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3222077

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2022290634

Country of ref document: AU

Ref document number: AU2022290634

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2022733376

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022290634

Country of ref document: AU

Date of ref document: 20220609

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202280055181.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2022733376

Country of ref document: EP

Effective date: 20240109